Recent advances in drug delivery systems for glaucoma treatment

Patel, Kapil D.; Silva, Lady V. Barrios; Park, Yuli; Shakouri, Taleen; Keskin-Erdogan, Zalike; Sawadkar, Prasad; Cho, Kyong Jin; Knowles, Jonathan C.; Chau, David; Kim, Hae‐Won

doi:10.1016/j.mtnano.2022.100178

Cited by 28 publications

(20 citation statements)

References 306 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…( vi ) Rise in IOP and oxidative stress in the glaucoma-conditioned eye finally led to damage to retinal ganglion cells and optical nerves. Reproduced from Patel et al [ 10 ], Elsevier, 2022.…”

Section: Figurementioning

confidence: 99%

Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

et al. 2023

View full text Add to dashboard Cite

Glaucoma is a degenerative, chronic ocular disease that causes irreversible vision loss. The major symptom of glaucoma is high intraocular pressure, which happens when the flow of aqueous humor between the front and back of the eye is blocked. Glaucoma therapy is challenging because of the low bioavailability of drugs from conventional ocular drug delivery systems such as eye drops, ointments, and gels. The low bioavailability of antiglaucoma agents could be due to the precorneal and corneal barriers as well as the low biopharmaceutical attributes of the drugs. These limitations can be overcome by employing nanoparticulate drug delivery systems. Over the last decade, there has been a lot of interest in chitosan-based nanoparticulate systems to overcome the limitations (such as poor residence time, low corneal permeability, etc.) associated with conventional ocular pharmaceutical products. Therefore, the main aim of the present manuscript is to review the recent research work involving the chitosan-based nanoparticulate system to treat glaucoma. It discusses the significance of the chitosan-based nanoparticulate system, which provides mucoadhesion to improve the residence time of drugs and their ocular bioavailability. Furthermore, different types of chitosan-based nanoparticulate systems are also discussed, namely nanoparticles of chitosan core only, nanoparticles coated with chitosan, and hybrid nanoparticles of chitosan. The manuscript also provides a critical analysis of contemporary research related to the impact of this chitosan-based nanomedicine on the corneal permeability, ocular bioavailability, and therapeutic performance of loaded antiglaucoma agents.

show abstract

Section: Figurementioning

confidence: 99%

Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In 1960, Wichterle O from Prague and Lim D from the Czech Republic were the first to discover hydrogels. They used synthetic polymer poly-2-hydroxyethyl methacrylate for preparing contact lenses [ 4 , 26 ]. Due to the high-water holding capacity, elastic in nature, compatibility with living tissue, and adaptability made hydrogels as a broad choice of use in various fields [ 27 ].…”

Section: Hydrogelsmentioning

confidence: 99%

Novel Hydrogels for Topical Applications: An Updated Comprehensive Review Based on Source

Almoshari

2022

Gels

View full text Add to dashboard Cite

Active pharmaceutical ingredients (API) or drugs are normally not delivered as pure chemical substances (for the prevention or the treatment of any diseases). APIs are still generally administered in prepared formulations, also known as dosage forms. Topical administration is widely used to deliver therapeutic agents locally because it is convenient and cost-effective. Since earlier civilizations, several types of topical semi-solid dosage forms have been commonly used in healthcare society to treat various skin diseases. A topical drug delivery system is designed primarily to treat local diseases by applying therapeutic agents to surface level parts of the body such as the skin, eyes, nose, and vaginal cavity. Nowadays, novel semi-solids can be used safely in pediatrics, geriatrics, and pregnant women without the possibility of causing any allergy reactions. The novel hydrogels are being used in a wide range of applications. At first, numerous hydrogel research studies were carried out by simply adding various APIs in pure form or dissolved in various solvents to the prepared hydrogel base. However, numerous research articles on novel hydrogels have been published in the last five to ten years. It is expected that novel hydrogels will be capable of controlling the APIs release pattern. Novel hydrogels are made up of novel formulations such as nanoparticles, nanoemulsions, microemulsions, liposomes, self-nano emulsifying drug delivery systems, cubosomes, and so on. This review focus on some novel formulations incorporated in the hydrogel prepared with natural and synthetic polymers.

show abstract

“…This is time consuming and predisposes patients to several adverse effects, such as temporary blurred vision, ocular discomfort, and damage to the ocular surface. Especially upon long-term use and in chronic eye conditions, these disadvantages lead to low patient compliance and treatment failure (Gholizadeh et al, 2021;Patel et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

“…Among them, nanoparticle-based systems have gained significant attraction due to their potential to improve ocular retention (Janagam et al, 2017;Jumelle et al, 2020). In addition, encapsulation into nanoparticles may prevent biologic and enzymatic degradation of drugs and, as a result, lower concentrations may be sufficient to achieve the desired therapeutic effects (Formica et al, 2021;Patel et al, 2022). The surface properties of nanoparticles, such as hydrophobicity or hydrophilicity and charge, can be easily tuned to increase the affinity towards ocular tissues and enable closer contact with the mucin layer on the ocular surface (Janagam et al, 2017;Patel et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

“…In addition, encapsulation into nanoparticles may prevent biologic and enzymatic degradation of drugs and, as a result, lower concentrations may be sufficient to achieve the desired therapeutic effects (Formica et al, 2021;Patel et al, 2022). The surface properties of nanoparticles, such as hydrophobicity or hydrophilicity and charge, can be easily tuned to increase the affinity towards ocular tissues and enable closer contact with the mucin layer on the ocular surface (Janagam et al, 2017;Patel et al, 2022). Nanoparticles can also be modified to release the encapsulated drug in a sustained manner and enhance drug permeability (Jumelle et al, 2020) using excipients such as chitosan (Wadhwa et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Therapeutic Benefits of Nanoencapsulation in Drug Delivery to the Anterior Segment of the Eye: A Systematic Review

et al. 2022

View full text Add to dashboard Cite

Background: Although numerous nanoparticle formulations have been developed for ocular administration, concerns are being raised about a possible mismatch between potential promises made by the field of nanoparticle research and demonstration of actual therapeutic benefit. Therefore, the primary focus of this present review was to critically assess to what extent nanoencapsulation of ocular drugs improved the therapeutic outcome when treating conditions in the anterior segment of the eye.Methods: A systematic search was conducted using Medline, PubMed, and Embase databases as well as Google Scholar for published peer-reviewed articles in English focusing on conventional nanoparticles used as drug delivery systems to the anterior segment of the eye in in vivo studies. The major therapeutic outcomes were intraocular pressure, tear secretion, number of polymorphonuclear leucocytes and pupil size. The outcome after encapsulation was compared to the non-encapsulated drug.Results: From the search, 250 results were retrieved. Thirty-eight studies met the inclusion criteria. Rabbits were used as study subjects in all but one study, and the number of animals ranged from 3 to 10. Coated and uncoated liposomes, lipid-based and polymeric nanoparticles, as well as micelles, were studied, varying in both particle size and surface charge, and encapsulating a total of 24 different drugs, including 6 salts. The majority of the in vivo studies demonstrated some improvement after nanoencapsulation, but the duration of the benefit varied from less than 1 h to more than 20 h. The most common in vitro methods performed in the studies were drug release, transcorneal permeation, and mucin interaction.Discussion: Nanoparticles that are small and mucoadhesive, often due to positive surface charge, appeared beneficial. Although in vitro assays can unravel more of the hidden and sophisticated interplay between the encapsulated drug and the nanoparticle structure, they suffered from a lack of in vitro—in vivo correlation. Therefore, more research should be focused towards developing predictive in vitro models, allowing rational design and systematic optimization of ocular nanoparticles with minimal animal experimentation.

show abstract

Recent advances in drug delivery systems for glaucoma treatment

Cited by 28 publications

References 306 publications

Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

Recent Progress in Chitosan-Based Nanomedicine for Its Ocular Application in Glaucoma

Novel Hydrogels for Topical Applications: An Updated Comprehensive Review Based on Source

The Therapeutic Benefits of Nanoencapsulation in Drug Delivery to the Anterior Segment of the Eye: A Systematic Review

Contact Info

Product

Resources

About